Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2022

Open Access 01-12-2022 | Coronary Heart Disease | Research

Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study

Authors: Li Liu, Zhenguo Wu, Yifan Zhuang, Yerui Zhang, Huiliang Cui, Fanghong Lu, Jie Peng, Jianmin Yang

Published in: Cardiovascular Diabetology | Issue 1/2022

Login to get access

Abstract

Background

The triglyceride–glucose (TyG) index is known as a reliable alternative marker of insulin resistance (IR), which has been regarded as a predictor of cardiovascular disease (CVD). However, whether TyG index can predict the risk and occurrence of CVD in non-diabetic population remains uncertain. The aim of this study was to explore the association between the TyG index and cardiovascular risk factors and to clarify the prognostic value of the TyG index for CVD, coronary heart disease (CHD) and stroke in non-diabetic general population in Eastern China.

Methods

A total of 6095 cases without diagnosed diabetes and CVD were included. The TyG index was calculated as ln (fasting triglyceride [mg/dL] × fasting glucose [mg/dL]/2) and the participants were divided into 4 groups according to the TyG index quartiles (Q1, Q2, Q3, Q4). The primary outcome was CVD, including CHD and stroke. Cox proportional hazards regression analysis was used to investigate the association between the TyG index and the risk of CVD.

Results

During the 10-year follow-up, 357 (5.9%) participants of CVD, 224 (3.7%) participants of CHD and 151 (2.5%) participants of stroke were observed. The incidence of CVD increased with the TyG index quartiles. Multivariate Cox regression analysis showed that the hazard ratios [95% confidence interval (CI)] in Q4 group were respectively 1.484 (1.074–2.051) for CVD, 1.687 (1.105–2.575) for CHD and 1.402 (0.853–2.305) for stroke compared to Q1 group. Moreover, adding the TyG index to models with traditional risk factors yielded a significant improvement in discrimination and reclassification of incident CVD and CHD.

Conclusions

The TyG index is associated with cardiovascular risk factors and can be used as a useful, low-cost predictive marker for CVD and CHD risk in non-diabetic population.
Appendix
Available only for authorised users
Literature
1.
GBD Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.CrossRef
2.
Hong S, Han K, Park CY. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(1):361.PubMedPubMedCentralCrossRef
3.
de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer’s disease. Front Biosci (Elite Ed). 2012;4(4):1582–605.PubMedCrossRef
4.
Cho YK, Han KD, Kim HS, Jung CH, Park JY, Lee WJ. Triglyceride–glucose Index is a useful marker for predicting future cardiovascular disease and mortality in young Korean adults: a nationwide population-based cohort study. J Lipid Atheroscler. 2022;11(2):178–86.PubMedPubMedCentralCrossRef
5.
Guo W, Zhu W, Wu J, Li X, Lu J, Qin P, Zhu C, Xu N, Zhang Q. Triglyceride Glucose Index is associated with arterial stiffness and 10-year cardiovascular disease risk in a Chinese population. Front Cardiovasc Med. 2021;8: 585776.PubMedPubMedCentralCrossRef
6.
Liu Q, Cui H, Ma Y, Han X, Cao Z, Wu Y. Triglyceride–glucose index associated with the risk of cardiovascular disease: the Kailuan study. Endocrine. 2022;75(2):392–9.PubMedCrossRef
7.
Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–12.PubMedCrossRef
8.
Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride–glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8.PubMedPubMedCentralCrossRef
9.
Yang L, Wu H, Jin X, Zheng P, Hu S, Xu X, Yu W, Yan J. Study of cardiovascular disease prediction model based on random forest in eastern China. Sci Rep. 2020;10(1):5245.PubMedPubMedCentralCrossRef
10.
Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.PubMedCrossRef
11.
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr. 1998;68(4):899–917.CrossRef
12.
Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, Elisaf M, Tsolas O. Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem. 2000;33(7):549–55.PubMedCrossRef
13.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef
14.
Hill MA, Jaisser F, Sowers JR. Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness. Cardiovasc Res. 2022;118(1):130–40.PubMedCrossRef
15.
16.
Reusch JE, Draznin BB. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab. 2007;9(4):455–63.PubMedCrossRef
17.
Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, Sowers JR. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.PubMedCrossRef
18.
Jia G, Sowers JR. Endothelial dysfunction potentially interacts with impaired glucose metabolism to increase cardiovascular risk. Hypertension. 2014;64(6):1192–3.PubMedCrossRef
19.
Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab. 2003;17(3):305–22.PubMedCrossRef
20.
Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity—correlation with gold standard is not enough. BMC Med Res Methodol. 2018;18(1):64.PubMedPubMedCentralCrossRef
21.
Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride–glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.PubMedPubMedCentralCrossRef
22.
Ding X, Wang X, Wu J, Zhang M, Cui M. Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol. 2021;20(1):76.PubMedPubMedCentralCrossRef
23.
Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46(2):189–97.PubMedCrossRef
24.
Jiao Y, Su Y, Shen J, Hou X, Li Y, Wang J, Liu B, Qiu D, Sun Z, Chen Y, et al. Evaluation of the long-term prognostic ability of triglyceride–glucose index for elderly acute coronary syndrome patients: a cohort study. Cardiovasc Diabetol. 2022;21(1):3.PubMedPubMedCentralCrossRef
25.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.PubMedCrossRef
26.
Zhang Y, Ren L, Ren M, Yang H, Li K, Cong H, Guo Z. Correlation between the Triglyceride–glucose Index and High Risk of cardiovascular disease: a cohort study of 102,061 subjects from Tianjin, China. Risk Manag Healthc Policy. 2021;14:2803–10.PubMedPubMedCentralCrossRef
27.
Rojas-Humpire R, Olarte-Durand M, Medina-Ramirez S, Gutierrez-Ajalcriña R, Canaza JF, Huancahuire-Vega S. Insulin resistance indexes as biomarkers of lifetime cardiovascular risk among adults from Peru. J Nutr Metab. 2021;2021:6633700.PubMedPubMedCentralCrossRef
28.
da Silva A, Caldas A, Hermsdorff H, Bersch-Ferreira ÂC, Torreglosa CR, Weber B, Bressan J. Triglyceride–glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovasc Diabetol. 2019;18(1):89.PubMedPubMedCentralCrossRef
29.
30.
Wang A, Tian X, Zuo Y, Chen S, Meng X, Wu S, Wang Y. Change in triglyceride–glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study. Cardiovasc Diabetol. 2021;20(1):113.PubMedPubMedCentralCrossRef
31.
Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, Liu Y, Liu J, Qi J, Ran S, et al. Burden of cardiovascular diseases in China, 1990–2016: findings from the 2016 global burden of disease study. JAMA Cardiol. 2019;4(4):342–52.PubMedPubMedCentralCrossRef
32.
Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019;394(10204):1145–58.PubMedPubMedCentralCrossRef
33.
Ma X, Cui H, Sun M, Liu Q, Liu X, Li G, Wei Y, Fu Q, Liu S, Cao L. Fasting blood glucose, cholesterol, and risk of primary liver cancer: the Kailuan STUDY. Cancer Res Treat. 2021;53(4):1113–22.PubMedPubMedCentralCrossRef
34.
Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394–405.PubMedCrossRef
35.
Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, Teliewubai J, Zhang Y, Xu Y. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019;18(1):95.PubMedPubMedCentralCrossRef
36.
Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, Shi S. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci Rep. 2019;9(1):7320.PubMedPubMedCentralCrossRef
37.
Barzegar N, Tohidi M, Hasheminia M, Azizi F, Hadaegh F. The impact of triglyceride–glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study. Cardiovasc Diabetol. 2020;19(1):155.PubMedPubMedCentralCrossRef
38.
Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, Zhang W, Zheng T, Yang J. Triglyceride–glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142.PubMedPubMedCentralCrossRef
39.
Zhu Y, Liu K, Chen M, Liu Y, Gao A, Hu C, Li H, Zhu H, Han H, Zhang J, et al. Triglyceride–glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20(1):137.PubMedPubMedCentralCrossRef
Metadata
Title
Association of triglyceride–glucose index and traditional risk factors with cardiovascular disease among non-diabetic population: a 10-year prospective cohort study
Authors
Li Liu
Zhenguo Wu
Yifan Zhuang
Yerui Zhang
Huiliang Cui
Fanghong Lu
Jie Peng
Jianmin Yang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2022
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-022-01694-3

Other articles of this Issue 1/2022

Cardiovascular Diabetology 1/2022 Go to the issue

Research

The predictive value of the triglyceride—glucose index for cardiovascular events in patients with coronary chronic total occlusion

Original investigation

Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk

Research

High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study

Research

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study

Research

Hemoglobin A1C as a prognostic factor and the pre-diabetic paradox in patients admitted to a tertiary care medical center intensive cardiac care unit

Research

Prognostic impact of changes in aortic stiffness for cardiovascular and mortality outcomes in individuals with type 2 diabetes: the Rio de Janeiro cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits